What is Ventum Cap Mkts’ Estimate for TSE:MDP Q1 Earnings?

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Ventum Cap Mkts lifted their Q1 2026 earnings per share estimates for shares of Medexus Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Ventum Cap Mkts analyst M. Czmielewski now expects that the company will post earnings of ($0.09) per share for the quarter, up from their previous estimate of ($0.10). Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.12) EPS.

Several other equities research analysts have also recently weighed in on the stock. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Stifel Nicolaus upped their price objective on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. One research analyst has rated the stock with a buy rating and five have issued a strong buy rating to the stock. Based on data from MarketBeat, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average target price of C$5.58.

Medexus Pharmaceuticals Stock Down 6.5 %

Medexus Pharmaceuticals stock opened at C$4.60 on Monday. The stock has a 50-day simple moving average of C$3.30 and a 200 day simple moving average of C$2.74. The stock has a market capitalization of C$112.84 million, a price-to-earnings ratio of 92.00 and a beta of 1.96. Medexus Pharmaceuticals has a 12-month low of C$1.47 and a 12-month high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.